(Q33367606)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Dominique C Valla

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

9

Gluckman E

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Peffault de Latour R

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Asselah T

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Scieux C

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Devergie A

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Ribaud P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Espérou H

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Traineau R

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Marcellin P

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Socié G

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

English

0 references

publication date

1 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

709-713

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16062173%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705120

4 January 2020

exact match

0 references

cites work

Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Hepatitis C virus in long-term bone marrow transplant survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Therapy of hepatitis C: patients with normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Long-term outcome of hepatitis C infection after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120

inferred from DOI database lookup

7 January 2021

based on heuristic

Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705120